

# REAL-WORLD DATA ON INFECTION PREVALENCE IN PATIENTS ON IMMUNOSUPPRESSIVE TREATMENT WITH USTEKINUMAB, GOLIMUMAB AND GUSELKUMAB.



5PSQ-048



COPENHA  
GEN 2025



29<sup>TH</sup> EAHP CONGRESS  
12-13-14 MARCH  
PERSON CENTRED PHARMACY -  
NAVIGATING DIGITAL HEALTH



Hospital Universitario  
de Móstoles

I. OTERINO MOREIRA<sup>1</sup>, C. AGUILAR CASADO<sup>2</sup>, S. SANCHEZ SUAREZ<sup>3</sup>, M.M. GARCIA GIMENO<sup>2</sup>, L. CORRALES PEREZ<sup>1</sup>, C. CALDERON ACEDOS<sup>1</sup>, M. SEGURA BEDMAR<sup>1</sup>.


1. MOSTOLES UNIVERSITY HOSPITAL, PHARMACY DEPARTMENT, MOSTOLES, SPAIN.
2. THE ESCORIAL UNIVERSITY HOSPITAL, PHARMACY DEPARTMENT, SAN LORENZO DE EL ESCORIAL, SPAIN.
3. SAN CARLOS CLINICAL HOSPITAL, PHARMACY DEPARTMENT, MADRID, SPAIN.

[ivan.oterino.moreira@salud.madrid.org](mailto:ivan.oterino.moreira@salud.madrid.org)

## Background, importance and aim



**Ustekinumab** (anti IL 12 y 23)  
**Golimumab** (anti- TNF $\alpha$ )  
**Guselkumab** (anti IL 23)



Monoclonal antibodies against specific molecules that regulate the **immune response**



Rheumatoid arthritis  
Psoriatic arthritis  
Juvenile idiopathic arthritis  
Axial spondyloarthritis  
Plaque psoriasis  
Ulcerative colitis  
Crohn's disease

**AIM** To describe the **prevalence of infection with real-life data** in patients treated with ustekinumab, golimumab or guselkumab in their funded indications in the national health system.

## Materials and Methods



Retrospective  
observational



Mostoles University  
Hospital



December 2010-  
August 2024



Ustekinumab  
Golimumab  
Guselkumab



**Exclusion** → treatment of less than 3 months, given the long half-life of the drugs (2-3 weeks)



**Clinical History**  
(PC y HC)

**Demographic variables:** sex, date of birth

**Clinical variables:** date of start and discontinuation of treatment, line of biological treatment, concomitant chronic systemic immunosuppressive drug, reason for discontinuation and vaccination history

Treated **infections** during the treatment period both in primary care (PC) and hospital care (HC)

## Results



30 treatments  
27 patients

Psoriatic arthritis (9/27)  
Axial spondyloarthritis (8/27)  
Crohn's disease (4/27)  
Rheumatoid arthritis (3/27)  
Ulcerative colitis (2/27)  
Plaque psoriasis (1/27)

### Prevalence of infection per patient, median (IQR)

1 infection (IQR 0-2)

Ustekinumab (13/30)  
Golimumab (12/30)  
Guselkumab (5/30)

Organ/system	n	Infection	n
Upper respiratory tract infection	13	COVID-19	2
		Influenza	1
		Cold	6
		Bronchitis	2
		Tonsillitis	2
Skin and soft tissue infection	7	Herpes simplex virus	2
		Infected skin wound	2
		Skin abscess	2
		Paronychia	1
Urinary tract infection	5	Cystitis	5
Intestinal infection	2	Gastroenteritis	2
Oral-dental infection	2	Thrush	1
		Tooth abscess	1
Eye infection	1	Conjunctivitis	1
Reproductive tract infection	1	Vulvar abscess	1

0 serious infections, 4/31 moderate y 27/31 mild

## Conclusion and relevance

- We found a **low prevalence of infection** in patients treated with ustekinumab, golimumab and guselkumab.
- **Upper respiratory tract infections**, followed by **skin and soft tissue infections** and **urinary tract infections**, are the **most frequent**.
- In **90%** of cases these infections **were mild**